Nventa Biopharmaceuticals

Contact
nventacorp.com
+1858202-4900

Nventa Biopharmaceuticals Corporation

4370 La Jolla Village Drive, Suite 400
92122 San Diego
USA
+1858202-4900
nventacorp.com
Contact
Profile Products News
Contact

About Nventa Biopharmaceuticals

Nventa Biopharmaceuticals Corp and Akela Pharma Inc merged on May 21, 2009.

Akela is an integrated product development company primarily focused on therapeautics for pain utilizing proprietary drug delivery technologies. Akela's lead product candidate is Fentanyl TAIFUN, a fentanyl formulation specifically designed to be delivered with Akela's TAIFUN Multi-Dose Inhaler.

Read more about Nventa Biopharmaceuticals
Facts about Nventa Biopharmaceuticals
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of Nventa Biopharmaceuticals

Product portfolio

Show all

News about Nventa Biopharmaceuticals

Nventa Biopharmaceuticals

31-Mar-2009 | business & finance

Akela and Nventa announce merger

Akela Pharma Inc. and Nventa Biopharmaceuticals announced the execution of an arrangement agreement to combine the two companies by way of a plan of ...

Read news
Nventa Biopharmaceuticals

31-Jul-2008 | politics & laws

Nventa Wins European Patent Challenge Covering Lead Product Candidate HspE7 and Other HPV Therapeutics

Nventa Biopharmaceuticals Corporation announced that it has received a favorable decision from the Technical Board of Appeal of the European Patent Office ...

Read news
Nventa Biopharmaceuticals

30-Jul-2008 | research and development

Nventa Announces Final Data from HspE7 Phase 1 Cervical Dysplasia Trial

Nventa Biopharmaceuticals Corporation announced that it has completed analysis of immunological data from all four cohorts of its Phase 1 clinical trial ...

Read news
Nventa Biopharmaceuticals

01-Aug-2007 | people

Nventa assembles group of international experts for its Clinical and Scientific Advisory Board

Nventa Biopharmaceuticals Corporation announced that it has assembled a Clinical and Scientific Advisory Board. The Board will be instrumental in providing ...

Read news
Nventa Biopharmaceuticals

07-May-2007 | research and development

Nventa granted U.S. patent covering heat shock protein fusion to treat anogenital warts

Nventa Biopharmaceuticals Corporation announced that the U.S. Patent and Trademark Office has issued Patent Number 7,211,411 B2 to Nventa covering the use ...

Read news
Nventa Biopharmaceuticals

01-Feb-2007 | research and development

Nventa granted U.S. patent covering heat shock protein fusion to treat influenza

Nventa Biopharmaceuticals Corporation announced that the U.S. Patent and Trademark Office has issued Patent Number 7,157,089 to Nventa. The patent provides ...

Read news
Nventa Biopharmaceuticals

22-Jun-2006 | research and development

Nventa strengthens patent portfolio with two new European Patents for HPV-related diseases

Nventa Biopharmaceuticals Corporation announced that the European Patent Office has granted two patents to Nventa related to HspE7, its investigational ...

Read news
Nventa Biopharmaceuticals

19-Jun-2006 | research and development

Nventa announces positive HspE7 data from NCI-sponsored clinical trial in HIV-positive patients

First Clinical Evidence that HspE7 May Have Activity in Immunocompromised Patients

Read news
Show more news about Nventa Biopharmaceuticals

Here you will find Nventa Biopharmaceuticals Corporation